Yes, we have already a lot of AI tools commercially available. Not all of them are approved for clinical use. This varies a lot amongst different countries, but all pathologists are already allowed to use any AI tool as long as the pathologist also evaluates each case. So they can use the AI tool as long as it is an aid tool, and the pathologist is going to evaluate manually as well...
Yes, we have already a lot of AI tools commercially available. Not all of them are approved for clinical use. This varies a lot amongst different countries, but all pathologists are already allowed to use any AI tool as long as the pathologist also evaluates each case. So they can use the AI tool as long as it is an aid tool, and the pathologist is going to evaluate manually as well. But they can already sign out each case using AI as a supplementary tool. So this is already being done. And we have different companies offering different algorithms for these distinct biomarkers. So it’s already the present. It’s not the future. It is being used already. The problems now are access. We have to have a way to make these tools available widely. We have problems with infrastructure and costs. So to use any AI tool, you have to digitize all your slides. So your routine in clinical practice has to be digitized. You have to go through digital transformation. And this demands a lot of infrastructure and cloud space. And some of all of these things are pricey. So this changes a lot also in different countries. So it’s a challenge in developed countries and low-income countries. This can be really challenging. So I think what is not going to be widely available for now because of access, not because of technology and not because you cannot use it already in clinical practice. So here in the US, it is going to be used already. We have some algorithms already approved by the FDA, others not. Where I’m from in Brazil, we also have institutions already applying AI tools as well. And this is hugely important because all our findings show that we saw an increase in sensitivity and accuracy and also in concordance amongst pathologists in identifying HER2 IHC scores and HER2 clinical categories, matching more with a reference score of HER2 IHC. So we become better in identifying the patients who will benefit more from targeted treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
